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Abstract: The aim of this work was to investigate effects of the formulation factors on tablet printability
as well as to optimize and predict extended drug release from cross-linked polymeric ibuprofen
printlets using an artificial neural network (ANN). Printlets were printed using digital light processing
(DLP) technology from formulations containing polyethylene glycol diacrylate, polyethylene glycol,
and water in concentrations according to D-optimal mixture design and 0.1% w/w riboflavin and 5%
w/w ibuprofen. It was observed that with higher water content longer exposure time was required
for successful printing. For understanding the effects of excipients and printing parameters on
drug dissolution rate in DLP printlets two different neural networks were developed with using
two commercially available softwares. After comparison of experimental and predicted values of
in vitro dissolution at the corresponding time points for optimized formulation, the R2 experimental
vs. predicted value was 0.9811 (neural network 1) and 0.9960 (neural network 2). According to
difference f1 and similarity factor f2 (f1 = 14.30 and f2 = 52.15) neural network 1 with supervised
multilayer perceptron, backpropagation algorithm, and linear activation function gave a similar
dissolution profile to obtained experimental results, indicating that adequate ANN is able to set out
an input–output relationship in DLP printing of pharmaceutics.
Keywords: three-dimensional printing; additive manufacturing; digital light processing technology;
printlets; neural networks; optimization; prediction
1. Introduction
Three-dimensional printing (3DP) is an additive manufacturing process that allows the fabrication
of three-dimensional solid objects of virtually any shape from a 3D model file [1–3]. The basic
mechanism for most types of 3D printing is the same (layer-by-layer production of 3D objects from
digital designs) [4], but the difference lies in input materials and operating principles. There are
several types of 3D printing technologies: fused deposition modeling (FDM)—based on extrusion [5],
selective laser sintering (SLS)—based on powder bed fusion [6], stereolithography (SLA), and digital
light processing technology (DLP)—based on photopolymerization of the resin and others [2]. SLA
3D printing was the first rapid prototyping method developed and perhaps the most popular due to
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its superior resolution and accuracy [7]. DLP is a “sister technology” to SLA as the only significant
difference between these technologies is the light source used to cure the resin. SLA printers use lasers
combined with galvanometers to cure the resin while in DLP 3D printers, the light source is a specially
developed digital light projector screen. Due to the presence of this screen, DLP is generally considered
to be faster and more efficient than SLA [8]. The main drawbacks of SLA and DLP technology are the
limited number of photocrosslinkable polymers that are available for medical applications, and these
materials are currently not on the generally recognized as safe (GRAS) list of excipients [9].
Research in the field of oral drug delivery using SLA and DLP is still very limited. Wang et al.
who fabricated 4-aminosalicylic acid and paracetamol loaded printlets, showed no drug degradation
during the 3D printing process. [7]. In the study by Martinez et al. percentage of water in the initial
formulation was varied, showing that the crosslinking density is slightly modified as the water content
increases (up to 30%) and this dilution with water did not seem to significantly affect the speed at
which the drug was released [9]. Influence of geometry on the drug release profiles was investigated by
Martinez et al. [10]. In the study by Kadry et al. theophylline, as a model drug, and two photoreactive
polymers, polyethylene glycol diacrylate (PEGDA) and polyethylene glycol dimethacrylate (PEGDMA),
were used. Polymer concentration was varied to produce sturdy printlets with minimum polymer
concentration applying, for the first time, DLP technology [11]. Optimization techniques have not yet
been applied in 3D DLP fabrication and optimization of solid oral dosage forms.
The most frequently used optimization technique is design of experiments (DoE), but with the
development of computer science, artificial neural network (ANN) have attracted a lot of attention.
Despite the advantages of DoE-based polynomial model fitting, often the developed models show bad
fit resulting to a poor optimum estimation. An alternative approach that has been successfully applied
in cases where conventional DoE methods prove inadequate is the use of feed-forward ANNs [12].
Neural networks create their knowledge by detecting the patterns and relationships in data. It is a
biologically inspired computer-based system formed from hundreds of single units, artificial neurons,
connected with coefficients (units) which constitute the neural structure. The artificial neuron takes one
or more inputs and creates an output, which is passed on to another neuron. One of the most useful
advantages of artificial neural networks is their ability to generalize. The multilayered perceptron (MLP)
neural network is one of the simplest ANNs and consists of an input layer, output layer, and one or more
hidden layers of neurons. During the ‘training process’ the system is able to establish the relationship
between inputs and outputs using algorithms designed to alter the weights of the connections in the
network to produce a desired signal flow. Although MLP has proved efficient in solving an important
number of pharmaceutical development problems, no single software or modeling algorithm can
solve ‘all’ problems [13–16]. There are a few examples in literature describing combination of DoE
and ANN with recognized possibility as a powerful tool in predicting optimal conditions from a
low number of experiments [17]. DoE enable determination of the quantitative relationship between
selected input variables and responses while ANNs often exhibit superior performance in prediction
of the responses for given values of inputs [18]. ANN can be used in completing one portion of data in
the experimental design data pool, resulting in satisfying results for some outputs, considering the
number of experimental data used for modeling [19].
The aim of this work was to investigate the effects of formulation factors on printability as well as
to optimize and predict extended drug release from cross-linked polymeric ibuprofen printlets using
ANN created in two different softwares. For a meticulous investigation of the effects of excipients on
drug release, ANN was used because it is highly recommended to present the complicated relations
and strong nonlinearity between different parameters [20]. The prediction and optimization method
was applied to the development of ibuprofen extended-release 3D printlets using MLP and the
backpropagation algorithm with linear and log-sigmoid activation functions.
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2. Materials and Methods
PEGDA, average MW 700, was obtained from Sigma–Aldrich, Tokyo, Japan. Polyethylene glycol
(PEG 400, average MW 400) was purchased from Fagron B.V., Rotterdam, The Netherlands. Ethanol,
absolute was purchased from Honeywell Riedel-de-Haën™, Seelze, Germany and 2-propanol was
obtained from Merck KGaA, Darmstadt, Germany. Ibuprofen (Ph. Eur. 9.0) was used as a model
substance, PEGDA as the photopolymerizable monomer, while PEG 400 and water were used to alter
the cross-linking density. PEG 400 is chemically similar to PEGDA and the difference is that does not
have photopolymerizable terminal groups. Riboflavin (Ph. Eur. 9.0) was used as the photo-initiator.
The photo-initiator converts to reactive radicals upon exposure to light to catalyze the polymerization of
the formulation. In photopolymerization reactions different photo-initiators can be used, and riboflavin
is reported as pharmacologically non-toxic photo-initiator [9,21,22].
2.1. Preparation of Photopolymer Solution
Based on preliminary experiments, lower and upper limits (% w/w) of each component were
selected as follows: PEGDA (30.0–74.6%), PEG 400 (10.0–54.6%), water (10.0–30%), and amounts of
ibuprofen and riboflavin were kept constant, 5.0% and 0.1% respectively. Eleven formulations were
prepared according to D-optimal mixture design from Design Expert software 7.0.0 (Stat-Ease Inc.,
Minneapolis, MN, USA). Compositions of the formulations obtained by the software are given in
Table 1. Firstly PEGDA, PEG 400, and ibuprofen were mixed with propeller mixer Heidolph RZR2020
(Heidolph, Schwabach, Germany) until complete dissolution (approximately 60 min). Riboflavin and
water were added next, keeping the solution protected from light and with constant mixing until
complete dissolution (approximately 45 min). Compositions of three test formulations were selected
so that they differ from the previous 11 and were prepared in the same way. Approximately the same
concentration of PEGDA and PEG 400 was selected in the placebo formulation. Percentage of water
was varied from 10 to 30 in formulations F1–F11, based on which 15% of water was chosen in the
placebo formulation.
Table 1. Composition (% w/w) of the initial resins used to print the printlets.
Formulation PEGDA PEG 400 Water riboflavin ibuprofen
F1 32.10 32.60 30.00 0.10 5.00
F2 30.00 44.10 20.50 0.10 5.00
F3 74.60 10.00 10.10 0.10 5.00
F4 62.40 21.80 10.50 0.10 5.00
F5 50.60 34.00 10.00 0.10 5.00
F6 65.80 11.20 17.70 0.10 5.00
F7 30.00 54.60 10.00 0.10 5.00
F8 58.10 10.00 26.60 0.10 5.00
F9 39.30 45.30 10.00 0.10 5.00
F10 46.20 23.10 25.40 0.10 5.00
F11 40.40 35.60 18.70 0.10 5.00
Test 1 35.00 47.90 12.00 0.10 5.00
Test 2 55.00 24.90 15.00 0.10 5.00
Test 3 65.00 7.90 22.00 0.10 5.00
F placebo 42.50 42.40 15.00 0.10 0.00
2.2. Printing Dosage Forms
In this study a DLP printer, based on photopolymerization process, was used for fabrication of
solid oral dosage forms, called printlets. The DLP printer offers fast and efficient printing by projecting
the light onto a whole layer at once, while the SLA printer prints each layer in a line by line pattern.
The advantage of the Wanhao DLP printer is an open software and the possibility for adjustment of
parameters for printing a particular mixture [11]. A schematic view of the printing process is shown in
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Figure 1. The template used to print the printlets (a cylinder, 10.00 mm diameter, 3.02 mm height) was
designed with Autodesk Fusion 360 (Autodesk Inc, San Rafael, CA, USA) (Figure 2a) and exported as
a stereolithography file (stl) into the 3D printer software (Creation Workshop X). All 3D printlets were
printed with a Wanhao Duplicator 7 printer (Wanhao, Zhejiang, China) with layer thickness of 100 µm,
bottom exposure 800 s, and 10 bottom layers. Trial-and error approach was used to establish exposure
time for successful printing. In screening formulations, ibuprofen content was 5.0% and the water
content was varied from 5.0% to 30.0%. The minimum exposure time which lead to solidification was
selected. This criterion for exposure time allowed printing to be as short as possible.
Figure 1. Digital light processing technology (DLP) printing process.
Figure 2. (a) 3D model of DLP printlet; (b) DLP printlet
2.3. Characterization of Printlets
2.3.1. Determination of Physical and Mechanical Properties
Three-D printed printlets were washed with 2-propanol to remove any uncured liquid formulation
on the surface immediately after fabrication, then they were weighed and measured (diameter and
thickness, n = 10) using a caliper. The breaking force of printlets (n = 10) was measured using a
hardness tester Erweka TBH 125D (Erweka, Langen, Germany). Microscopic observations of placebo
and optimal printlets were done under a polarized light microscope Olympus BX 51P (Olympus, Tokyo,
Japan). Photos were acquired using cellSens Entry Version 1.14 software (Olympus, Tokyo, Japan).
2.3.2. Determination of Drug Concentration in 3DP Printlets
Printed printlets were crushed using mortar and pestle (n = 3), and 200 mg of the crushed printlet
was diluted with 10 mL of ethanol. Samples were placed in an ultrasonic bath Bandelin–Sonorex
RK102H (Sonorex–Bandelin, Berlin, Germany) at room temperature and sonicated for 15 min to enhance
extraction of ibuprofen. At the end of sonification, dispersions were cooled to room temperature
and then filtered through a 0.45 µm Millipore filter (Merck Millipore Ltd. Carrigtwohill, County
Cork, Ireland) A sample of 250 µL of the solution was diluted to 50 mL with phosphate buffer pH 6.8.
Amount of drug in solution was determined using UV–Vis spectroscopy Evolution 300 (Thermo–Fisher
Scientific, Waltham, MA, USA) at the wavelength of 221 nm. Corresponding placebo samples were
analyzed in order to nullify the possible effect of other printlet constituents on drug absorbance.
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2.3.3. Dissolution Test Conditions
Drug release profiles were obtained using the paddle apparatus Erweka DT 600 (Erweka, Langen,
Germany). The printlets were placed in 900 mL of phosphate buffer pH 6.8 for 8 h. The paddle speed
of the USPII was fixed at 75 rpm, and the tests were conducted at 37 ± 0.5 ◦C. Buffer samples of 4 mL
were withdrawn at predetermined time intervals, filtrated through a 0.45 µm Millipore filter (Merck
Millipore Ltd. Carrigtwohill, County Cork, Ireland), and the absorbance of released ibuprofen was
measured UV-spectrophotometrically at the wavelength of the relative maximum absorbance (221 nm).
Studies were performed in triplicate.
2.3.4. Kinetic Model
A number of mathematical models have been proposed to describe drug release from
pharmaceutical delivery systems [23,24]. Drug release profiles were fitted into four mathematical
models including zero-order, first-order, Higuchi, and Korsmeyer–Peppas.
2.3.5. Differential Scanning Calorimetry (DSC)
DSC was used to study the thermal properties of placebo and optimal printlets. DSC analyses
were performed on a DSC 1 differential scanning calorimeter Mettler Toledo AG (Analytical, Zurich,
Switzerland). Accurately weighed 5–10 mg of samples (optimal and placebo formulation) were placed
in pierced aluminum pans, and subjected to heating at 10 ◦C/min in the range of −50–200 ◦C under
nitrogen purge gas flow of 50 mL/min. An empty pan was used as a reference.
2.4. Artificial Neural Network Modeling
To get better insight in an input–output relationship in DLP printing of ibuprofen printlets in
ANN modeling, two artificial neural networks, using different commercially available software, were
used. Each software has unique potential in solving problems.
(1) Neural Network 1. Commercially available STATISTICA 7.0 Neural Networks software (StatSoft
Inc., Tulsa, OK, USA.) was used throughout the study. For prediction and optimization of
ibuprofen release from 3D DLP printlets, supervised MLP and backpropagation algorithm with
linear activation function were used. The data set was split into training (8 formulations),
validation (2 formulations) and test (1 formulation) subsets. Amount of PEGDA, PEG 400,
and water (% w/w) in formulations were selected as input factors affecting the release of ibuprofen.
The cumulative percentage of ibuprofen release from 3D DLP printlets at time points of 1, 2, 4, 6,
and 8 h was used as output data (Table S1). A trial and error approach, conducted by varying
the number of layers and number of nodes in the hidden layer(s), was used to train the neural
network. Learning rate and momentum were 0.6, the number of layers was varied from 3 to 10,
and the number of nodes in the hidden layer(s) from 4 to 10. The criteria to choose the ´´ best MLP
model´´ were minimal test error and maximum coefficient of determination R2 for observed vs.
predicted values. After the training process, the prediction ability of the developed network was
examined by external validation with the unseen samples of three test formulations.
(2) Neural Network 2. Another approach was the usage of commercial software MATLAB
R2014b (The MathWorks, Inc., Natick, MA, USA) to investigate the combination of process
and formulation factors on optimization of ibuprofen release. A supervised MLP network and
backpropagation algorithm with linear and log-sigmoid activation functions were used for the
prediction. Percentage of PEGDA, PEG 400, and water in formulations were selected as input
factors affecting the release of ibuprofen, as well as exposure times (s). The cumulative percentage
of ibuprofen released after 2, 4, 6, and 8 h was the output data (Table S2). The most optimal MLP
model was chosen based on the maximum R and minimal normalized mean square error between
the calculated and target output for the test data. After the training process was finished, the
prediction was examined by external validation with the unseen test (optimal formulation).
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2.5. Optimization of 3D Printed Printlets
D-optimal mixture design was established by data predicted using evaluated MLP, because this
approach of using DoE-based modeling to decipher the black-box nature of the ANNs resulted in
satisfying results. Data obtained using DoE enable the development of more accurate models and
improve process understanding [19]. The desirability function approach has been proven to be a useful
statistical tool, the most widely used in industry, for solving multi-variable problems and optimization
of one or several responses [19,23]. The objective function, D(X), called the desirability function is used
in this method. It reflects the desirable ranges for each response (di) from zero to one (least to most
desirable respectively). The simultaneous objective function is a geometric mean of all transformed
responses. The numerical optimization technique was used to generate the composition of formulation
with desirable drug release. The criteria for the selection of the optimal formulation were the percentage
of in vitro release at time points of 2, 4, 6, and 8 h—not more than 30%, 60%, and 70%, and not <80%,
respectively. The importance of the first two goals was set with two pluses, and the importance of the
next two goals was set with three pluses, as they were more significant. After determination of the
optimal composition of the formulation, the formulation was prepared, characterized by dissolution
test, and the obtained results from the dissolution test were compared with the predictions by neural
network 1 and neural network 2. Predictability was expressed through calculation of the coefficient of
determination (R2), f 1 (difference factor) and f 2 (similarity factor). Difference and similarity factor are
represented in Equations (1) and (2).
f1 =
(∑n
t=1|Rt− Tt|∑n
t=1 Rt
)
× 100 (1)
f2 = 50× log10

100√
1 +
∑n
t=1(Rt−Tt)2
n
 (2)
where n is the number of dissolution sampling times, and Rt and Tt are the mean percent dissolved at
each time point, t, for the experimental and predicted values of drug released, respectively.
3. Results and Discussion
3.1. Printing Process
With 5.0% of the water in screening formulations, printlets were successfully fabricated with an
exposure time of 100 s. There was no solidification of the resins with lower exposure time. The increase
in water content up to 10.1% required exposure time to be at least 400 s, and with 30.0% water in the
formulation, printing was possible at exposure time of 800 s due to which the process lasted for a long
time. The water content affected the exposure time to the light projector so that with the increase in
the content of water in the formulation, longer exposure time was required, and that was criteria for
setting printing parameters in the way presented in Table 2. The minimal exposure time which lead to
solidification was selected to keep printing time as short as possible.
It was observed that for every formulation it is necessary to find adequate printing parameters
with a trial and error approach because there is no guideline for process parameters selection
for mixtures containing photopolymers for pharmaceutical application. A similar observation
was reported in the study by Robles-Martinez et al. [24]. Exposure time for every formulation
was longer than reported in the published paper by Kadry et al., but in this published paper
2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone was used as the photo-initiator, theophylline
as the active substance, and the content of the formulation was different as well as their
characteristics [11].
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Table 2. Printing process parameters.
Formulation Exposure Time (s) Bottom Exposure (s) Layer Thickness (mm) Bottom Layers
F1 800.00 800.00 0.10 10.00
F2 800.00 800.00 0.10 10.00
F3 400.00 800.00 0.10 10.00
F4 400.00 800.00 0.10 10.00
F5 500.00 800.00 0.10 10.00
F6 600.00 800.00 0.10 10.00
F7 400.00 800.00 0.10 10.00
F8 800.00 800.00 0.10 10.00
F9 400.00 800.00 0.10 10.00
F10 800.00 800.00 0.10 10.00
F11 600.00 800.00 0.10 10.00
Test 1 400.00 800.00 0.10 10.00
Test 2 500.00 800.00 0.10 10.00
Test 3 600.00 800.00 0.10 10.00
F placebo 600.00 800.00 0.10 10.00
3.2. Characterization of Printlets
3.2.1. Physical and Mechanical Properties and Drug Content
A DLP printer was able to fabricate 3D printlets with ibuprofen similar to results obtained by
Martinez et al [9]. A DLP printlet as well as a 3D model are presented in Figure 2. All fabricated
printlets had a smooth surface and consistency in shape. Measured tablet weight, dimensions, hardness,
and drug load (mean ± SD) are shown in Table 3.
For better determination of the effects of the formulation factors on obtained mechanical
characteristics of printlets, the content of PEGDA, PEG 400, and water were evaluated as the input
variables for D-optimal mixture design. Three responses, weight, hardness, and drug load, separately,
were fitted to linear, quadratic, special cubic, and full cubic models. The best-fitting mathematical
model was selected based on several statistical parameters including adjusted R-squared, predicted
R-squared, and predicted residual sum of square (PRESS) (Table 4). The focus was on the model
maximizing the adjusted R-squared and the predicted R-squared. The linear model was considered
the best fitted model for each of the three responses.
Table 3. Measured tablet weight, dimensions, hardness, and drug load (mean ± SD).
Formulation Weight (mg) Diameter (mm) Thickness (mm) Hardness (N) Drug Load (mg)
F1 387.00 ± 45.20 11.13 ± 0.62 3.00 ± 0.00 47.33 ± 3.21 24.11 ± 2.51
F2 378.00 ± 29.00 10.86 ± 0.31 3.09 ± 0.20 32.00 ± 17.00 23.00 ± 1.58
F3 323.40 ± 21.60 10.81 ± 0.31 3.00 ± 0.00 108.33 ± 23.71 15.00 ± 1.00
F4 296.70 ± 4.50 10.17 ± 0.26 3.02 ± 0.04 92.33 ± 29.02 14.40 ± 0.22
F5 354.40 ± 21.10 10.55 ± 0.38 3.00 ± 0.00 33.00 ± 4.58 22.30 ± 0.13
F6 278.90 ± 11.50 10.04 ± 0.09 3.00 ± 0.00 132.33 ± 18.88 18.30 ± 0.75
F7 345.10 ± 32.70 10.52 ± 0.32 2.99 ± 0.02 n.d.1 21.70 ± 2.05
F8 400.10 ± 42.90 12.40 ± 0.55 2.97 ± 0.23 29.67 ± 3.51 27.10 ± 2.91
F9 340.50 ± 19.50 10.60 ± 0.17 2.94 ± 0.13 19.00 ± 8.66 23.00 ± 1.13
F10 375.00 ± 28.70 11.53 ± 0.43 2.92 ± 0.11 37.00 ± 16.52 25.80 ± 1.98
F11 377.50 ± 37.30 11.40 ± 0.47 2.99 ± 0.12 35.00 ± 24.25 25.50 ± 2.53
1 n.d. not determined
Mathematically, the relationship for the studied variables was expressed in the following
Equations (3)–(5) in actual values. Dimensions of printlets were similar to 3D model but variation in
mass and dimension became greater for printlets containing more water. From Equation (3), water
had the greatest impact on weight. Water dilutes the formulation, reduces viscosity, and consequently
the reproducibility of printing with SLA printer [9]. Instead of the advantages of the DLP printer,
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previously mentioned, the reproducibility problem with customized resins has not been overcome
with this technology.
weight = 2.68392× PEGDA+3.78589× PEG400 + 6.42698×water (3)
hardness = 1.52104× PEGDA− 0.53285× PEG400− 0.28236×water (4)
drug load = 0.11399× PEGDA + 0.24544× PEG400 + 0.53252×water (5)
From results and Equation (4) it was observed that the content of PEGDA affected the hardness
of the printlets. For printlets with a higher content of PEGDA, greater force was required to break
printlets. PEG 400 and water had negative effects. With a higher content of PEG 400 or water, a lower
force was measured to break the printlet. Printlet F7 was too elastic, and the hardness tester could not
break them. Content of ibuprofen in printlets was greatly affected by the amount of water, with higher
water content higher drug content was observed. From Equation (5) there was also a positive effect of
PEGDA and PEG 400 on drug load. In a research paper by Martinez et al. it had been demonstrated
that the solubility of ibuprofen was increased with the presence of solvents like polyethylene glycol
300, which decreased the polarity of the aqueous solution [9]. Even if the represented mathematical
models do not achieve high values of R2 (R2 values reached 0.58, 0.57, 0.62, respectively), information
extracted through the analysis of the mathematical expressions can help to improve understanding of
the effects of formulation factors on characteristics of printlets.
Table 4. Model summary statistics.
Weight Linear Quadratic Special Cubic Cubic
Adjusted R2 0.4828 11,760.57 0.0573 0.5331
Predicted R2 0.2042 −2.6704 −4.744 −15888.43
PRESS 11,760.57 54,239.56 84,882.21 2.35 × 108
Hardness Linear Quadratic Special Cubic Cubic
Adjusted R2 0.4575 0.5454 0.4311 n.d.
Predicted R2 0.0542 −1.4961 −4.3319 n.d.
PRESS 13,171.03 34,759.87 74,249.53 n.d.
Drug load Linear Quadratic Special Cubic Cubic
Adjusted R2 0.5184 0.6846 0.6145 0.7212
Predicted R2 0.2228 −0.1716 −0.8126 −9,486.5367
PRESS 139.12 209.72 324.46 1.70 × 106
1 n.d. not determined
3.2.2. Dissolution Test
Dissolution profiles for all formulations are shown in Figure 3. Printlets fabricated with
cross-linkable photoreactive polymers, such as PEGDA, remained intact throughout the dissolution
test similar to published studies [11,25]. The fastest dissolution after 8 h was from formulation F7
(90.72 ± 5.06%) that had the highest concentration of PEG 400 (54.6% w/w), and the slowest dissolution
after 8 h was from F8 (38.04 ± 1.41%) that had the lowest concentration of PEG 400 (10% w/w) and high
concentration of PEGDA (58.1% w/w). In this study, it was observed that PEG 400 had a great influence
on the drug release profile, as it was concluded in the study by Wang et al. [7] that changes in the ratio
of PEGDA/PEG 300 played an important role in drug release rate. The reduction in the concentration
of PEGDA probably increases the drug release rate because of the lower degree of cross-linking in
the tablet matrix and increases in the proportion of PEG 400 affected the greater molecular mobility
in the tablet core. Formulation F2 had a high concentration of PEG 400 (44.1% w/w) and the lowest
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concentration of PEGDA (30% w/w) but dissolution after 8 h was slower than expected (45.69 ± 0.61%)
probably because of the interactions of excipients. The effect of excipients on ibuprofen released
after 8 h of dissolution on a 3D surface plot is shown in Figure 4. Martinez at al. [9] showed that
dissolution is the slowest from the formulation containing no water and gets faster as the water content
is increased, but this clear proportion between water and dissolution rate could not be observed in this
study. Martinez et al. used printing with the same process parameters for all formulations, but for the
formulations and printer used in this study, it was necessary to adjust the exposure time. By comparing
these observations, it can be concluded that not only excipients and their interactions but also printing
process parameters could effect drug dissolution rate. Effects of excipients could not be evaluated just
by observing modulation in their concentration; it was necessary to apply advanced software. Content
of PEGDA, PEG 400, and water were evaluated as the input variables for D-optimal mixture design to
determinate their effects on drug release, but the proposed mathematical model was not significant.
Because the relationships between the drug release profile of 3D DLP printlets and formulation factors
were not well understood, artificial neural networks were used for further research.
Figure 3. Dissolution profiles of ibuprofen printlets F1–F11 and Test 1–Test 3, ∆ exposure time 400 s,
× exposure time 500 s,  exposure time 600 s, • exposure time 800 s.
Figure 4. Cont.
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Figure 4. Interaction effect of excipients on ibuprofen released after 8 h of dissolution. (a) x- polyethylene
glycol (PEG) 400 (%), y—water (%), (b) x—polyethylene glycol diacrylate (PEGDA) (%), y—water (%),
(c) x—PEG 400 (%), y—PEGDA (%), z axis on all graphics—cumulative % of ibuprofen released after
8 h of dissolution test.
3.2.3. Drug Release Kinetic
To interpret the mechanism of drug release from the printlets, data were fitted into various kinetic
models such as zero-order, first-order, the Higuchi equation, and the Korsemeyer–Peppas equation.
The highest R2 coefficient determines the suitable mathematical model that best describes drug release
kinetics and n gave insights into the mechanism of drug release [26,27]. The most proper model fitted
to data based on having the closest R2 to 1 was the Higuchi model (R2 was between 0.9746 to 0.9993 for
all formulations, Table 5) meaning drug release was afforded through a diffusion process, square root
time dependent. In formulations F2 and F the optimum was predominately zero order kinetics but R2
for the Higuchi model was also high. The values of n less than 0.45 reveal that the diffusion pattern is
a kind of Fickian diffusion and values of n between 0.45 and 0.89 reveal that the diffusion pattern is
anomalous transport [28]. In the evaluated formulations there was predominately Fickian diffusion
as a mechanism of drug release, and during the dissolution test no erosion or swelling of printlets
was observed.
Table 5. Parameters obtained by fitting dissolution data to various mathematical models.
Formulation
Zero Order First Order Higuchi Korsmeyer–Peppas
k0 R2 k1 R2 kh R2 kkp R2 n
F1 0.0707 0.9859 0.0021 0.9428 1.9807 0.9945 5.3769 0.9780 0.3588
F2 0.0643 0.9881 0.0022 0.9348 1.7921 0.9861 3.9965 0.9777 0.3843
F3 0.0614 0.9866 0.0021 0.9498 1.7126 0.9886 4.5005 0.9739 0.3619
F4 0.0727 0.9642 0.0023 0.8935 2.0614 0.9982 4.1796 0.9977 0.4024
F5 0.0997 0.9379 0.0025 0.8345 2.8606 0.9922 3.9337 0.9950 0.4609
F6 0.0744 0.9427 0.0026 0.8285 2.1292 0.9940 2.3934 0.9932 0.4895
F7 0.1445 0.9775 0.0027 0.8961 4.0722 0.9985 4.7498 0.9985 0.4767
F8 0.0510 0.9285 0.0020 0.8493 1.4654 0.9871 4.0217 0.9962 0.3671
F9 0.0856 0.9746 0.0023 0.9089 2.4164 0.9993 4.8273 0.9972 0.4027
F10 0.0857 0.9591 0.0020 0.8963 2.4347 0.9957 7.4583 0.9968 0.3489
F11 0.1082 0.9744 0.0023 0.9089 3.0557 0.9989 5.5710 0.9958 0.4147
Test 1 0.1552 0.9758 0.0031 0.8732 4.3715 0.9959 3.0129 0.9980 0.5535
Test 2 0.1045 0.9641 0.0031 0.8563 2.9500 0.9891 1.8925 0.9944 0.5656
Test 3 0.0776 0.9685 0.0029 0.8875 2.1940 0.9959 1.9670 0.9969 0.5144
F optimal 0.1286 0.9892 0.0029 0.9516 3.5609 0.9749 3.5776 0.9544 0.4872
ko—zero order rate constant, k1—first order rate constant, kh—Higuchi dissolution constant, kkp—Korsmeyer
release rate constant, R2—coefficient of determination, n—drug release exponent,
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3.3. Development of Artificial Neural Network Models
(1) Neural network 1. In the process of creating the most appropriate neural network 1 it was found
that increasing the number of layers decreased the coefficient of determination (Figure 5). One
hidden layer is normally adequate to provide an accurate prediction and more than one hidden
layer can be used for modeling complex problems [29]. Selected MLP had a minimum root mean
square (RMS = 0.0296) and the highest coefficient of determination (R2 = 0.9994) for obtained vs.
predicted values of cumulative drug release for two formulations. Hence, a network consisting
of three input and five output units, with eight hidden units arranged in a single hidden layer
was selected. MLP was tested with a set of test data. Three test formulations (Test 1, 2, 3) were
prepared and examined in the same test conditions as formulations F1–F11. A correlation plot
was constructed of the experimentally obtained responses and those predicted by MLP. The
square coefficient R2 was 0.9478 (Figure 6a).
(2) Neural network 2. For the second version of the ANN, where exposure times were used as inputs
as well as percentage of PEGDA, PEG 400, and water, correlation plots of predicted and obtained
values of drug release for all formulations (training, validation, and test) showed that the MLP
model had a regression plot with coefficient R2 = 0.99877, which indicated that the optimum MLP
model was reached (Figure 6b). An optimal neural network with neural network 2 was achieved
using five hidden layers with the number of units being 5, 5, 6, 5, and 6 per layer. The data set
consisted of training (90% of samples) and validation (10% of samples) subsets.
Architecture of developed neural networks is presented in Figure 7.
Figure 5. Coefficient of determination (R2) for neural network 1 with different numbers of hidden
nodes and layers (a) for 3 and 4 layers (b) for 5 to 10 layers.
Figure 6. Predicted and experimental cumulative % of ibuprofen release (a) for the test dataset in
neural network 1 and (b) for the whole dataset (training, validation, and test) in neural network 2.
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Figure 7. (a) Architecture of neural network 1 and (b) architecture of neural network 2.
3.4. Optimization and Characterization of Optimal Formulation
The optimal formulation according to the desirability function approach consisted of: PEGDA
30%, PEG 400 52.89%, water 12.02%, riboflavin 0.10%, and ibuprofen 5.00%, and printing was done
in the same way as test formulations with exposure time of 400 s, bottom exposure 800 s, layer
thickness 0.1, and 10 bottom layers. Predicted drug release at time points of 2, 4, 6, and 8 h was 41.96%,
63.34%, 70.00%, and 79.99% respectively. Fabricated optimal and appropriate placebo formulation was
observed under a polarized light microscope and cross-sections are shown in Figure 8. On cross-section
of printlets, layers were clearly visible which demonstrated the printing process, but inside of layers
in both placebo and optimal printlet undefined structures could be observed. The reasons for their
appearance have not been clarified.
Figure 8. (a) Cross-section of placebo tablet; (b) cross-section of optimal tablet
DSC curves of placebo and optimal printlets are represented in Figure 9. The combination of a
sharp peak near 0 ◦C and a broad peak below 0 ◦C was observed for the optimal printlet, suggesting
co-existence of free and loosely bound water in this formulation. Loosely bound water is associated
with non-freezing water and interacts weakly with the ether oxygen, a hydrogen bonded complex
between water molecules similar to that in bulk water [30]. The broad endotherm near 100 ◦C in
both placebo and optimal formulations reflects water loss upon heating [9]. No melt endotherm
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characteristics for ibuprofen are seen, indicating that the drug dissolves in the polymer and/or the water.
The solubility of the drug is increased with the presence of solvents like PEG 400, which decreases the
polarity of the aqueous solution [9,31]. The exothermic peak near −40◦C present in optimal printlets
and non-present in placeboes indicates a glass transition temperature of ibuprofen and the presence of
ibuprofen in the amorphous phase [32,33].
Figure 9. Differential scanning calorimetry (DSC) curves of placebo and optimal printlet.
A dissolution test was performed under the same conditions as the test formulations and results
are represented in Table 6 and graphically in Figure 10. For the optimal ibuprofen DLP printlet,
comparison of release profiles predicted by neural network 1 and neural network 2 and experimental
results was done by calculation of f 1 and f 2. Obtained values for neural network 1 are f 1 = 14.30 and
f 2 = 52.15, and for neural network 2 are f 1 = 22.34 and f 2 = 44.91.
Table 6. Predicted and experimental in vitro release values at time points of 2, 4, 6, and 8 h for optimal
formulation of 3D DLP printlets.
Time (h) Predicted Values (%)Neural Network 1
Predicted Values (%)
Neural Network 2 Experimental Values (%)
2 41.96 45.37 29.85
4 63.34 62.77 51.18
6 70.00 76.66 65.73
8 79.99 88.46 76.60
Figure 10. Experimental and predicted dissolution test profiles.
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Two different neural networks were developed to test possibilities of understanding the effect of
excipients on ibuprofen release. After comparison of predicted and experimental values of in vitro
dissolution at the corresponding time points for optimized formulation, the R2 experimental vs.
predicted value was 0.9811 (neural network 1) and 0.9960 (neural network 2). These values are very
close to 1.0, with neural network 2 having a slightly higher R2 value compared to neural network 1.
In machine learning, the correlation coefficient and coefficient of determination are usually adopted as
evaluation metrics for regression problems. However, the correlation coefficient and the coefficient of
determination cannot properly evaluate the performance of the pharmaceutical formulation prediction
models. Thus, specific criteria suitable for pharmaceutics should be introduced to evaluate the model
performance [34]. In vitro dissolution profiles can be compared by a model-independent method
which includes the difference factor (f 1) and the similarity factor (f 2) [35]. Obtained values of f 1 and f 2
for neural network 1 and 2 showed that neural network 1 gave a similar dissolution profile to obtained
experimental results. In developing an optimal formulation, the importance of the first two goals
was set with two pluses, and the importance of the next two goals (drug release at 6 and 8 hours)
was set with three pluses. From the profiles, it is visible that predicted values at 6 and 8 hours were
closer to the real values. Neural network 2 was created with combination of formulation and process
parameters. Generally, the main limitation regarding the neural networks is the small number of
experiments available, as a higher number of experiments would increase the accuracy of the neural
network and this will be done in future studies. ANN with possibilities to provide an understanding
of the relationship of input–output variables and give better insights into the effects of excipients
and process parameters on dissolution rate could help in optimization of formulating processes and
printing printlets according to patient’s needs.
There are a lot of printing process and formulation parameters and their effects on printlet
characteristics are still unknown. Further research will be conducted with the aim to investigate the
applicability of combination of ANN and DLP technologies for other drugs and to investigate the
effect of formulation and process parameters on characteristics of printlets matrix created with 3D
printing technology.
4. Conclusions
DLP technology, as a type of 3D printing technology, can be used for the production of
extended-release ibuprofen printlets with PEGDA, PEG 400, and water as the main ingredients,
and riboflavin as a photo-initiator. It is necessary to adjust printing parameters for every formulation
because of the effect of excipients on the success of printing. The relationship between excipients
and drug release in tested formulations is complex and non-linear. Artificial neural networks with
their ability to generalize can be a useful tool for understanding the effects of excipients on printlets
characteristics with the aim to print printlets with the desired drug release. No single software or
modeling algorithm can solve “all” problems, but for better prediction and optimization, application
of different softwares can be a helpful method. In this study it was demonstrated that adequate ANN
is able to understand the input–output relationship in DLP printing of pharmaceutics.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/10/544/s1:
Table S1: Dataset for neural network 1 and Table S2: Dataset for neural network 2.
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